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OBJECTIVES: Clinical trials have shown that ranibizumab is efficacious in 
improving vision among patients with AMD. The objectives of this study are to: 
1) evaluate whether as needed (PRN) is as effective as monthly treatment; and 
2)compare the efficacy of ranibizumab 0.5mg treatment with: a)control; 
b)ranibizumab 0.3mg; and c)bevacizumab. METHODS: This is a systematic meta-
analysis review of 8 randomized controlled clinical phase III or IV trials with a 
minimum of one year follow-up that investigated the efficacy of ranibizumab in 
treating AMD. The dependent variables were effect sizes of visual acuity gained 
and odds ratios of percentage of patients who gained ≥15 visual acuity letters. 
Weighted multiple regression analyses were used to compare the monthly 
versus PRN treatment. RESULTS: Regression results showed no significant 
differences in efficacy between PRN and monthly treatment. The ranibizumab to 
control (placebo injection/surgery) comparison (4 effect sizes, 4 odds ratios, 
N=1047): showed that ranibizumab had significantly higher improvement in 
visual acuity (g=1.20, z=7.83, p<0.05) and a higher proportion of patients who 
gained ≥15 letters (OR: 6.37; 95% CI 3.96-9.98; p<0.05). When comparing 
ranibizumab dose (6 effect sizes, 5 odds ratios, N=3449): ranibizumab 0.5mg 
showed significantly higher improvement in letters gained (g=0.08, z=2.34, 
p<0.05) than ranibizumab 0.3mg. However, the proportion of patients who gained 
≥15 letters was not significantly different. The ranibizumab to bevacizumab 
comparison (3 effect sizes, 3 odds ratios, N= 800) revealed no significant 
differences. CONCLUSIONS: Ranibizumab 0.5mg was found to be more effective 
than control and ranibizumab 0.3mg. Monthly treatment was not significantly 
different from PRN. More clinical trials are needed to compare the efficacy of 
ranibizumab and bevacizumab.  
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OBJECTIVES: To investigate the burden and epidemiology of glaucoma in a large 
health maintenance organization (HMO) in Israel. METHODS: A retrospective 
cohort study, conducted using the electronic medical databases of Maccabi 
Healthcare Services (MHS), a 2 million member HMO in Israel. The study 
population consisted of all patients who were newly diagnosed with glaucoma 
between 2003 and 2010 at MHS. In addition, for prevalence calculation we 
included all patients who are currently (2012) active members of MHS. Collected 
data included personal characteristic, relevant surgical procedures, anti-
glaucoma medications, caregiver characteristics, comorbidity, possible 
complications (asthma, depression, cardiovascular diseases, cataract) and all-
cause mortality. We investigated the age- and sex-specific prevalence and 
incidence rates, and compared the medical comorbidity and mortality of 
glaucoma patients to the general HMO population. RESULTS: A total of 26,196 
prevalent glaucoma patients aged 40 or above were identified among active 
members of MHS in 2012 with an average prevalence of 35 per 1000. Prevalence 
was strongly associated with increasing age, ranging from 7 cases per 1000 at age 
45-50 to 212 per 1000 at age 85+. The 4 main prevalent pathologies among MHS 
population aged 40 or above were open angle glaucoma, pre or borderline 
glaucoma, unspecified glaucoma, and pseudo exfoliation with prevalence rates 
of 2%, 1.4%, 0.9% and 0.2%, respectively. A total of 11,512 incident glaucoma 
patients, who were diagnosed between 2003 and 2010 were identified, with an 
average incidence of 2.5 per 1000 among 40+ year old members. Overall, 1.5% of 
the study patients have undergone glaucoma surgery, 3% were blind and 41% 
were diagnosed with cataract. CONCLUSIONS: The current study demonstrates 
the potential use of automated medical databases to estimate the burden of 
glaucoma and its complications. The increased comorbidity and mortality 
among these patients has important implication for health authorities for 
prevention and delivery of health-care services.  
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OBJECTIVES: The epidemiology of pathologic myopia (PM), an important cause of 
visual impairment worldwide, is poorly understood. This study analyzed data 
from a large US claims database to estimate the prevalence and incidence of PM 
and PM + retinal neovascularization (RNV). METHODS: Data were drawn from 
the MarketScan® Commercial Claims and Encounters database and Medicare 
Supplemental and Coordination of Benefits in the USA. ICD9 diagnostic codes for 
PM (360.21) and both PM + RNV (362.16) were used to identify cases; use of the 
diagnostic code on at least one occasion was required. A 1-year disease-free 
period was required for a diagnosis to be considered an incident case. RESULTS: 
MarketScan covered 45,226,794 patients in 2011; 43,581 and 1,781prevalent cases 
of PM and PM + RNV were identified, representing a prevalence of 9.64 (95% CI: 
9.55–9.73) and 0.39 (95% CI: 0.38–0.41) per 10,000 population, respectively. 
Incidence per 10,000 persons in 2011 was 2.75 (95% CI: 2.70–2.80) for PM and 0.09 
(95% CI: 0.08–0.10) for PM + RNV. Subjects with incident PM had a mean age of 
47.9±18.5 years, 46.5% were under 50 years old, and 62.3% were females, whereas 
subjects with PM + RNV had a mean age of 55.1±14.5, 30.3% were younger than 
50 years old, and 71.1% were females. CONCLUSIONS: Prevalence and incidence 
estimates of PM among the commercially insured US population in 2011 were 
approximately 9.6 and 2.7 per 10,000 persons, respectively. PM+RNV represents 
approximately 3−4% of patients with PM. Using only one diagnostic code to 
identify cases may overestimate prevalence and incidence as there is potential 
to include some diagnoses that would later be ruled out as true cases. Both PM 
and PM+RNV are often diagnosed in individuals younger than 50 years of age and 
the majority of patients are female.  
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OBJECTIVES: Anti-VEGF therapy with ranibizumab (RBZ) dosed monthly 
improves visual acuity over time in patients with neovascular (“wet”) age-related 
macular degeneration (wAMD). In two identical phase 3 trials, IAI dosed 2mg 
every 2 months, following 3 initial monthly doses (2Q8) demonstrated clinically 
equivalent efficacy and a similar safety profile to RBZ 0.5mg dosed monthly 
(RQ4). We assessed the budgetary impact of adding IAI 2Q8 to a formulary of a 
hypothetical one million member US health plan. METHODS: A Markov model 
characterized treatment with IAI 2Q8 and RQ4 over time. Health states were 
based on visual acuity in the better-seeing eye. Efficacy and cost estimates came 
from clinical trial data and published literature. The model calculated direct 
medical costs, including costs of drug, administration, monitoring, visual 
impairment, and adverse events. Ten percent of patients were assumed to be 
treated in both eyes. We calculated budgetary impact by comparing estimated 
costs over three years from current (100% RBZ market share) through future 
scenarios (IAI market share: Year 1, 22%; Year 2, 42%; Year 3, 51%). Model 
outcomes include total costs over three years in current and future scenarios, 
net costs, and cost per-member per-month (PMPM). RESULTS: In a one million 
member plan, 2,800 were newly treated for wAMD. Total budget was $79.2 
million in Year 1, $147.9 million in Year 2 and $152.4 million in Year 3 in the 
current scenario, and $71.9 million, $126.5, and $121.2 million in Years 1, 2 and 3 
in the future scenario. Net budget impact ranged from $-7.3 million in Year 1 to 
$-31.2 million in Year 3, or $0.61, $1.78, and $2.60 PMPM savings in Years 1, 2, and 
3. CONCLUSIONS: Adding IAI 2Q8 to a US formulary saves money in the first 
three years, primarily due to reduced injection frequency compared to RQ4.  
 
PSS6  
COST ANALYSIS OF PARS PLANA VITRECTOMY FOR THE TREATMENT OF 
SYMPTOMATIC VITREOMACULAR ADHESION: A BOTTOM-UP COSTING 
PERSPECTIVE  
Nicod E1, Jackson T2, Grimaccia F1, Angelis A1, Kanavos P1 
1London School of Economics and Political Science, London, UK, 2King’s College Hospital, London, 
UK  
The direct cost to the NHS of pars plana vitrectomy (PPV) is unknown since a 
bottom-up costing exercise has not been undertaken. Health care resource group 
(HRG) costing relies on a top-down approach. OBJECTIVES: To quantify the direct 
cost of PPV for vitreomacular traction (VMT), epiretinal membrane (ERM) and 
macular hole (MH). METHODS: Each of five NHS vitreoretinal units recorded the 
indication for surgery and all procedure elements for a minimum of 30 
consecutive PPVs, to include at least 10 cases of VMT, ERM, or MH. In-surgery 
bottom-up costing was undertaken by prospectively recording all consumables, 
equipment and staff salaries associated with surgery, between March and 
September 2012. Out-of-surgery costs, namely before and after surgery between 
admission and discharge, were estimated based on accounting costs recorded in 
one site. RESULTS: Of 151 PPVs, 57 were for MH (16.6%), ERM (15.2%), or VMT 
(4%). The average surgical time was 1.22 hours [range 0.96-1.38], corresponding to 
an average staff cost of £280.40 [£184.90-£376.70]. The average cost of 
consumables was £534.60 [£406.55-£688.85], and of equipment £87.75 [£28.10-
£139.15]. The average direct cost of PPV in theatre was £901.10 [£671.00-£1185.55]. 
Average out-of-surgery costs were estimated at £325.35, including nursing staff, 
extra consumables and hospitalisation costs. This resulted in a total cost of 
£1673.80 [£1496.40-£1863.30], including 30% overheads. This cost estimate is 
considered an under-estimate because of lack of available data on departmental-
level general costs, medical and anaesthetic staff costs incurred out-of-surgery. 
The average effective HRG tariff reimbursed was £1701.20. CONCLUSIONS: These 
figures indicate that the real cost incurred is likely to be higher than the 
reimbursed tariff, but it may be cost-effective for NHS hospitals to undertake 
additional PPVs for VMT, ERM and MH, if they can amortise existing 
infrastructure with a sufficient number of interventions to benefit from 
economies of scale.  
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OBJECTIVES: Cochlear implants (CI) are electronic devices introduced surgically 
into the inner ear. This is the only medical treatment for profound total 
deafness. CI is particularly useful in children because they can have an impact 
on the children education. The aim of this study is to assess the cost and the 
educational impact of CI in French implanted children over a four year period 
METHODS: 268 profoundly deaf children were recruited and implanted between 
September 2002 and December 2004 in 16 specialized French hospitals. The 
educational impact was assessed in children aged less than 2 years and aged 
over 2 years using the educational rate evolution and the type of integrated 
